Join Growin Stock Community!

Alpha tau medical ltd.DRTS.US Overview

US StockHealthcare
(No presentation for DRTS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

DRTS AI Insights

DRTS Overall Performance

DRTS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

DRTS Recent Performance

-2.71%

Alpha tau medical ltd.

0.05%

Avg of Sector

-0.31%

S&P500

DRTS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

DRTS Key Information

DRTS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

DRTS Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Price of DRTS

DRTS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

DRTS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.47
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
8.71
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
13.88%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.47
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
8.71
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
13.88%

  • When is DRTS's latest earnings report released?

    The most recent financial report for Alpha tau medical ltd. (DRTS) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating DRTS's short-term business performance and financial health. For the latest updates on DRTS's earnings releases, visit this page regularly.

  • How much cash does DRTS have?

    At the end of the period, Alpha tau medical ltd. (DRTS) held Total Cash and Cash Equivalents of 3.33M, accounting for 0.03 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is DRTS's EPS continuing to grow?

    According to the past four quarterly reports, Alpha tau medical ltd. (DRTS)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.14. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What are the PEG ratio and PE ratio of DRTS?

    The latest valuation data shows Alpha tau medical ltd. (DRTS) has a Price-To-Earnings (PE) ratio of -8.08 and a Price/Earnings-To-Growth (PEG) ratio of -1.05. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.